64th ASH Annual Meeting and Exposition: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational II

Symposia: Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational Oral and Poster Abstracts
Oral

Research, Biological therapies, Translational Research, genomics, bioinformatics, Plasma Cell Disorders, Diseases, immune mechanism, Gene Therapy, Therapies, Immunotherapy, Lymphoid Malignancies, computational biology, Biological Processes, Technology and Procedures, molecular biology, Study Population, profiling, Human, omics technologies

R06-R09 (Ernest N. Morial Convention Center)

Moderators:

Arun P Wiita, MD, PhD, UCSF and Paola Neri, MD, PhD, University of Calgary

Disclosures:

Neri: Janssen: Consultancy, Honoraria; BMS: Consultancy, Honoraria; Sanofi-Aventis: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria.

2:00 PM

241

BRD9 Is Essential for Ribosome Biogenesis and the Survival of Multiple Myeloma Cells

Keiji Kurata¹^*, Mehmet K. Samur, PhD², Priscilla Liow³^*, Kenneth Wen⁴^*, Leona Yamamoto, MD⁵, Jiye Liu, PhD⁶^*, Eugenio Morelli, MD⁷, Annamaria Gulla, MD⁸, Yu-Tzu Tai, PhD⁴, Jun Qi, PhD⁹^*, Teru Hideshima, MD, PhD¹⁰ and Kenneth C. Anderson, MD³

¹Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
²The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA
³Dana-Farber Cancer Institute, Boston, MA
⁴Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Boston, MA
⁵Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Brookline, MA
⁶The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁷Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA
⁸Medical Oncology, Dana Farber Cancer Institute, Boston, MA
⁹Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
¹⁰Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston

2:15 PM

242

Single Cell Multiomic Analysis Reveals Relapsed and Refractory Multiple Myeloma Cells Associated with 1q, TP53, and PHF19 alterations That Affect Subclonal Chromatin Accessibility

Travis S Johnson, PhD^1,2, Parvathi Sudha, MS³^*, Enze Liu, PhD³^*, Vivek S. Chopra, PhD⁴^*, Cedric E. Dos Santos, PhD⁴, Michael Nixon, MSN, MPH⁵^*, Kun Huang, PhD^1,2^*, Rafat Abonour, MD³, Mohammad Issam Abu Zaid, MBBS³ and Brian A. Walker, PhD³

¹Department of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, IN
²Melvin and Bren Simon Comprehensive Cancer Center, Indiana University, Indianapolis, IN
³Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology Oncology, Indiana University, Indianapolis, IN
⁴Genentech, Inc., San Francisco, CA
⁵Genentech, Inc., South San Francisco, CA

2:30 PM

243

Multiomics Analysis of IMiD/CELMoD Resistant Multiple Myeloma Models Uncovers Novel and Targetable Vulnerabilities in the SREBP Lipid Synthesis Pathway

Sarah A. Bird, BMBCh^1,2, Amy Barber, PhD¹^*, Fernando J. Sialana, PhD¹^*, Marco P. Licciardello, PhD¹^*, Harvey Che, PhD¹^*, Habib Bouguenina, PhD¹^*, Yura Grabovska, PhD¹^*, Enze Liu, PhD³^*, Yakinthi Chrisochoidou, PhD¹^*, Shannon Martin, MRes¹^*, Jyoti Choudhary, PhD¹^*, Brian A. Walker, PhD³, Ian Collins, PhD¹^*, Paul Clarke, PhD¹^* and Charlotte Pawlyn, PhD^1,2

¹The Institute of Cancer Research, London, United Kingdom
²The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom
³Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology Oncology, Indiana University, Indianapolis, IN

2:45 PM

244

Single-Cell RNA Sequencing of Rare Circulating Tumor Cells in Precursor Myeloma Patients Reveals Molecular Underpinnings of Tumor Cell Circulation

Elizabeth D. Lightbody, PhD^1,2,3, Danielle T. Firer, BS³^*, Romanos Sklavenitis-Pistofidis, MD^1,2,3, Junko Tsuji, PhD³^*, Michael P. Agius, PhD^1,2,3^*, Ankit K. Dutta, PhD^1,2,3^*, Ting Wu, MS³^*, Hadley Barr, BA^1,2^*, Mahshid Rahmat, PhD^1,2,3^*, Yoshinobu Konishi, MD, PhD^1,3,4^*, Michelle P. Aranha, PhD^1,2,3^*, Michael Vinyard, MSc³^*, Jean-Baptiste Alberge, PhD^1,2,5^*, Nang Kham Su, MS²^*, Cody J. Boehner, BS^1,2^*, Laura Hevenor, BS²^*, Habib El-Khoury, MD^1,2, Katherine Towle, BS²^*, Christian J. Cea-Curry, BS^1,2^*, Erica Horowitz, BA²^*, Jacqueline Perry, MPH^1,2^*, Anna Cowan, BA²^*, Anna V. Justis²^*, Daniel Auclair, PhD⁶, Catherine R. Marinac, PhD^2,7, Gad Getz, PhD^1,5,8^* and Irene Ghobrial, MD^1,2,3

¹Department of Medicine, Harvard Medical School, Boston, MA
²Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
³Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA
⁴Department of Medical Oncology, Dana-Farber Cancer Institute, Brookline, MA
⁵Broad Institute of MIT and Harvard, Cambridge, MA
⁶Hematology R&D, AstraZeneca, Waltham, MA
⁷Harvard T.H. Chan School of Public Health, Boston, MA
⁸Department of Pathology, Massachusetts General Hospital Cancer Center, Boston, MA

3:00 PM

245

Discovery of Tumor Reactive T Cell Receptors in Newly Diagnosed Multiple Myeloma

Mirco Friedrich^1,2^*, Niklas Kehl¹^*, Simon Steiger³^*, Tim Robin Wagner¹^*, Katharina Lindner¹^*, Michael Kilian, PhD^1,4^*, Julius Michel¹^*, Sebastian Uhrig, PhD¹^*, Raphael Lutz, MD^2,5^*, Nina Prokoph, PhD^2,6^*, Alexandra M Poos, PhD²^*, Lukas John, MD²^*, Lilli Sophie Sester, MD²^*, Niels Weinhold, PhD²^*, Stefan Fröhling, MD^7,8, Edward W Green, PhD^1,4^*, Lukas Bunse, MD^1,4^*, Paola Neri, MD, PhD^9,10, Nizar Jacques Bahlis, MD¹⁰, Karsten Rippe, PhD³^*, Stefan Eichmüller, PhD¹^*, Carsten Müller-Tidow, MD^2,7^*, Hartmut Goldschmidt, MD^2,7, Michael Platten, MD^1,4,7^* and Marc S Raab, MD^1,2^*

¹German Cancer Research Center (DKFZ), Heidelberg, Germany
²Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany
³Division of Chromatin Networks, German Cancer Research Center (DKFZ) and BioQuant, Heidelberg, Germany
⁴Department of Neurology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
⁵Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany
⁶Clinical Cooperation Unit (CCU) Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany
⁷National Center for Tumor Diseases (NCT), Heidelberg, Germany
⁸Division of Translational Medical Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany
⁹Tom Baker Cancer Center, University of Calgary, Calgary, AB, Canada
¹⁰Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada

3:15 PM

246

Pathological RANK Signaling in Combination with TCL1 Drives a Multiple Myeloma-like Disease in Mice

Lisa Pfeuffer^1,2^*, Lisa Brandmeier, MSc^1,2^*, Nicole Beck^1,2^*, Katja Steiger³^*, Clemens-Martin Wendtner^4,5, Jürgen Ruland^1,2,6,7^* and Maike Buchner^1,2^*

¹Institute of Clinical Chemistry and Pathobiochemistry, School of Medicine, Technical University of Munich, Munich, Germany
²TranslaTUM - Central Institute for Translational Cancer Research, Technical University of Munich, Munich, Germany
³Institute of Pathology, Klinikum rechts der Isar, Technical University Munich, Munich, Germany
⁴Munich Clinic Schwabing, Academic Teaching Hospital, Ludwig-Maximilian University, Munich, Germany
⁵Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Klinikum Schwabing, Munich, Munich, Germany
⁶German Cancer Research Center (DKFZ), Heidelberg, Germany
⁷German Cancer Consortium (DKTK), Munich Partner Site, Munich, Germany

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

651.O3.3 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational II